RxDoctor Payments Data

Douglas Desantis, MD

Internal Medicine · Havelock, NCNPI 1275509705

Payments from drug & device makers

$1,104in general payments, 2019–2025

Across 64 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$367
  • Novo Nordisk$130
  • AbbVie$102
  • Johnson & Johnson$91
  • Pfizer$55
  • Lilly USA, LLC$46
  • plus $313 from 11 others

What the payments were for

  • Food & beverage$1,104100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,104 in reported general payments places this provider in the 75th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$196,472
Medicare patients
421
Services billed
7,259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$129,737
EliquisApixaban40$48,937
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$47,152
JardianceEmpagliflozin45$46,896
DescovyEmtricitabine/Tenofov Alafenam11$27,620
TrulicityDulaglutide27$26,953
XareltoRivaroxaban30$20,091
JanuviaSitagliptin Phosphate12$19,654
Tresiba Flextouch U-100Insulin Degludec26$19,168
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$17,279
LinzessLinaclotide29$15,636
Breo ElliptaFluticasone/Vilanterol22$8,667
Celecoxib125$3,214
Omeprazole186$2,928
Montelukast Sodium130$2,905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$130$129,737104 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$43$73,09996 claims
PfizerEliquis$55$48,93740 claims
Boehringer IngelheimJardiance$16$46,89645 claims
Lilly USA, LLCTrulicity$46$26,95327 claims
Johnson & JohnsonXarelto$91$20,09130 claims
AbbVieLinzess, Synthroid$102$17,81556 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Havelock

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →